Liquidia (LQDA) Share-based Compensation (QoQ) (2020 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Share-based Compensation (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.51% |
| Mar 31, 2026 | 27.91% |
| Dec 31, 2025 | -15.59% |
| Sep 30, 2025 | -3.93% |
| Jun 30, 2025 | -0.43% |
| Mar 31, 2025 | 77.46% |
| Dec 31, 2024 | -44.43% |
| Sep 30, 2024 | -3.81% |
| Jun 30, 2024 | -1.54% |
| Mar 31, 2024 | 274.57% |
| Dec 31, 2023 | -73.30% |
| Sep 30, 2023 | -0.43% |
| Jun 30, 2023 | 0.84% |
| Mar 31, 2023 | 423.37% |
| Dec 31, 2022 | -78.55% |
| Sep 30, 2022 | 7.81% |
| Jun 30, 2022 | 12.80% |
| Mar 31, 2022 | 82.27% |
| Dec 31, 2021 | -32.08% |
| Sep 30, 2021 | 12.49% |